Physician profile
Karen L Kish
NPI 1477820603
$2,100.72
in general payments reported to CMS, 2019-2025
22 companies · $696 in 2025
The $696 reported for 2025 was more than what 95% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $250 · 2022: $446 · 2023: $165 · 2024: $543 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,404.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $307.10 | 2022-2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Alk-Abello, INC | $235.69 | 2024-2025 | Ragwitek, Odactra, Grastek |
| Merck Sharp & Dohme LLC | $213.93 | 2021-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Corium, LLC | $190.09 | 2022-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $163.86 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $163.24 | 2021-2025 | Qelbree |
| Ars Pharmaceuticals Operations, INC. | $150.27 | 2025 | Neffy |
| Ironshore Pharmaceuticals INC. | $133.16 | 2022-2024 | |
| Neos Therapeutics, Lp | $89.23 | 2022-2025 | Adzenys Xr-Odt |
| Pfizer INC. | $87.85 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.67 | 2021-2025 | Elaprase |
| Kaleo, INC. | $59.60 | 2021-2022 | |
| Seqirus USA INC | $45.70 | 2022-2025 | Flucelvax |
| Cumberland Pharmaceuticals, INC. | $35.16 | 2021 | |
| Sanofi Pasteur INC. | $30.60 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomerieux INC | $21.00 | 2025 | Biofire Spotfire Control Station |
| Astrazeneca Pharmaceuticals Lp | $20.14 | 2025 | Flumist Quadrivalent |
| Alexion Pharmaceuticals, INC. | $19.01 | 2025 | Koselugo |
| Cranial Technologies, INC | $14.94 | 2022 | |
| Glaxosmithkline, LLC. | $14.67 | 2022 | |
| Adlon Therapeutics L.P. | $12.24 | 2021 | |
| Genentech USA, INC. | $7.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Kish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.